US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MetaVia Inc

0.7514

+0.05217.45%

Post-market: 0.7488-0.0026-0.35%17:47 EST

Volume:266.83K

Turnover:195.16K

Market Cap:18.19M

PE:-0.73

High:0.7588

Open:0.7200

Low:0.6869

Close:0.6993

52wk High:2.75

52wk Low:0.5555

Shares:24.21M

Float Shares:9.22M

Volume Ratio:0.34

T/O Rate:2.89%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0331

EPS(LYR):-3.5570

ROE:-168.18%

ROA:-58.41%

PB:2.87

PE(LYR):-0.21

Loading ...

Overview Company News Filings

Metavia Reports Positive Phase 2a Results for Vanoglipel in MASH Patients

Metavia Inc. Unveils Pipeline Advances Targeting Obesity and MASH

MetaVia Q3 EPS $(0.14) Beats $(0.25) Estimate

Metavia Inc. reports third quarter 2025 results and updates on clinical programs

MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726

MetaVia Inc expected to post a loss of 22 cents a share - Earnings Preview

Metavia Inc. Advances Obesity Treatment with New Clinical Study

MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025

Metavia Inc. to Present at H.C. Wainwright Liver Disease Virtual Conference

Metavia Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $12

THOMSON REUTERS

MetaVia Inc reports results for the quarter ended June 30 - Earnings Summary

MetaVia Inc expected to post a loss of 32 cents a share - Earnings Preview

Metavia Inc. Unveils New Presentation Highlighting Advances in Cardiometabolic Disease Therapies

Metavia Reports Second Quarter 2025 Financial Results And Provides Corporate Update

MetaVia Q2 EPS $(0.26) Beats $(0.31) Estimate

Metavia Inc. Reports Q2 2025 Results: Net Loss Narrows to $4M, EPS Improves to $0.26 from $1.85 Year-Over-Year

Metavia Inc - Qtrly Shr Loss $0.26

THOMSON REUTERS

BRIEF-Metavia Extends 48 Mg MAD Portion Of Its Phase 1 Clinical Trial Of Da-1726 For Treatment Of Obesity

MetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025

Metavia Extends 48 Mg Mad Portion of Its Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MTVA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":0.7514,"timestamp":1763413200000,"preClose":0.6993,"halted":0,"volume":266827,"hourTrading":{"tag":"盘后","latestPrice":0.7488,"preClose":0.7514,"latestTime":"17:47 EST","volume":1805,"amount":1322.5145472,"timestamp":1763419655383},"delay":0,"floatShares":9219300,"shares":24214788,"eps":-1.033085,"marketStatus":"Post-Mkt","change":0.0521,"latestTime":"11-17 18:00:19 EST","open":0.72,"high":0.7588,"low":0.6869,"amount":195155.9603477,"amplitude":0.102817,"askPrice":0.78,"askSize":100,"bidPrice":0.685,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.033085,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1763427600000},"marketStatusCode":4,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.6993,"preHourTrading":{"tag":"盘前","latestPrice":0.68,"preClose":0.6993,"latestTime":"09:15 EST","volume":1620,"amount":1115.503488,"timestamp":1763388926083},"postHourTrading":{"tag":"盘后","latestPrice":0.7488,"preClose":0.7514,"latestTime":"17:47 EST","volume":1805,"amount":1322.5145472,"timestamp":1763419655383},"volumeRatio":0.340242},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":9219300,"roa":"-58.41%","roe":"-168.18%","lyrEps":-3.556986,"volumeRatio":0.340242,"shares":24214788,"dividePrice":0,"high":0.7588,"amplitude":0.102817,"preClose":0.6993,"low":0.6869,"week52Low":0.5555,"pbRate":"2.87","week52High":2.75,"institutionHeld":0,"latestPrice":0.7514,"committee":0.818182,"eps":-1.033085,"divideRate":0,"volume":266827,"delay":0,"ttmEps":-1.033085,"open":0.72,"prevYearClose":2.03,"prevWeekClose":0.6993,"prevMonthClose":0.9925,"prevQuarterClose":0.9402,"fiveDayClose":0.8,"twentyDayClose":1.02,"sixtyDayClose":0.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"MTVA","fiscalQuarterEnding":"2025/09","expectedEps":-0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-07","symbol":"MTVA","fiscalQuarterEnding":"2025/06","expectedEps":-0.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-05-14","symbol":"MTVA","fiscalQuarterEnding":"2025/03","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.36},{"date":"2025-03-20","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742457600000,"name":null,"time":"Pre-Market","dateTimestamp":1742443200000,"actualEps":null},{"market":"US","date":"2024-11-07","symbol":"MTVA","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.55}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735794000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2025-11-14","current":-0.709041,"percent":0.179916,"low":-1.962939,"twenty":-0.895545,"median":-0.562464,"eighty":-0.481224,"high":-0.203888,"avg":-0.689147,"sd":0.34317,"marketCap":15981760},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270},{"date":"2025-04-25","current":-0.266622,"twenty":-0.631917,"median":-0.512617,"eighty":-0.463425,"marketCap":7356638},{"date":"2025-05-02","current":-0.239019,"twenty":-0.626947,"median":-0.506404,"eighty":-0.454331,"marketCap":6595010},{"date":"2025-05-09","current":-0.222708,"twenty":-0.618869,"median":-0.49874,"eighty":-0.452346,"marketCap":6144956},{"date":"2025-05-16","current":-0.238257,"twenty":-0.615141,"median":-0.497083,"eighty":-0.429105,"marketCap":5848960},{"date":"2025-05-23","current":-0.285534,"twenty":-0.611413,"median":-0.49458,"eighty":-0.263184,"marketCap":7009578},{"date":"2025-05-30","current":-0.543676,"twenty":-0.612655,"median":-0.49689,"eighty":-0.271352,"marketCap":13346706},{"date":"2025-06-06","current":-0.549972,"twenty":-0.608927,"median":-0.497673,"eighty":-0.281282,"marketCap":13501264},{"date":"2025-06-13","current":-0.597709,"twenty":-0.608927,"median":-0.503297,"eighty":-0.294785,"marketCap":14673160},{"date":"2025-06-20","current":-0.557862,"twenty":-0.607995,"median":-0.509511,"eighty":-0.332562,"marketCap":13694949},{"date":"2025-06-27","current":-0.542591,"twenty":-0.603956,"median":-0.515396,"eighty":-0.428478,"marketCap":13320078},{"date":"2025-07-03","current":-0.516978,"twenty":-0.602714,"median":-0.515103,"eighty":-0.429732,"marketCap":12691292},{"date":"2025-07-11","current":-0.572913,"twenty":-0.599701,"median":-0.516978,"eighty":-0.432869,"marketCap":14064436},{"date":"2025-07-18","current":-0.535431,"twenty":-0.597709,"median":-0.518414,"eighty":-0.439456,"marketCap":13144307},{"date":"2025-07-25","current":-0.587857,"twenty":-0.5965,"median":-0.521601,"eighty":-0.450482,"marketCap":14431313},{"date":"2025-08-01","current":-0.482926,"twenty":-0.587857,"median":-0.520838,"eighty":-0.453589,"marketCap":11855342},{"date":"2025-08-08","current":-0.674088,"twenty":-0.587857,"median":-0.518654,"eighty":-0.453589,"marketCap":12464564},{"date":"2025-08-15","current":-0.837521,"twenty":-0.602714,"median":-0.525504,"eighty":-0.453589,"marketCap":15486597},{"date":"2025-08-22","current":-0.836212,"twenty":-0.615141,"median":-0.534692,"eighty":-0.453589,"marketCap":15462399},{"date":"2025-08-29","current":-0.846681,"twenty":-0.624461,"median":-0.53558,"eighty":-0.454826,"marketCap":15655982},{"date":"2025-09-05","current":-0.898895,"twenty":-0.643102,"median":-0.537471,"eighty":-0.457336,"marketCap":16621475},{"date":"2025-09-12","current":-0.894708,"twenty":-0.675347,"median":-0.537746,"eighty":-0.459434,"marketCap":16544042},{"date":"2025-09-19","current":-1.200403,"twenty":-0.704615,"median":-0.540578,"eighty":-0.459802,"marketCap":22196650},{"date":"2025-09-26","current":-1.308626,"twenty":-0.720771,"median":-0.542033,"eighty":-0.464632,"marketCap":24197809},{"date":"2025-10-03","current":-1.285464,"twenty":-0.777314,"median":-0.543184,"eighty":-0.467223,"marketCap":23769507},{"date":"2025-10-10","current":-1.347885,"twenty":-0.814044,"median":-0.546792,"eighty":-0.468812,"marketCap":24923743},{"date":"2025-10-17","current":-1.360971,"twenty":-0.829721,"median":-0.548697,"eighty":-0.471608,"marketCap":25165721},{"date":"2025-10-24","current":-1.257721,"twenty":-0.836474,"median":-0.551486,"eighty":-0.475169,"marketCap":23256514},{"date":"2025-10-31","current":-1.275649,"twenty":-0.839353,"median":-0.556987,"eighty":-0.478202,"marketCap":23588024},{"date":"2025-11-07","current":-1.112332,"twenty":-0.856339,"median":-0.562326,"eighty":-0.479691,"marketCap":20568137},{"date":"2025-11-14","current":-0.985555,"twenty":-0.895545,"median":-0.562464,"eighty":-0.481224,"marketCap":15981760}],"updateTime":1763399973561},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581885386","title":"Metavia Reports Positive Phase 2a Results for Vanoglipel in MASH Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885386","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885386?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:31","pubTimestamp":1762522279,"startTime":"0","endTime":"0","summary":"MetaVia Inc. has announced positive new data from its Phase 2a clinical trial evaluating vanoglipel , an oral GPR119 agonist, for the treatment of metabolic dysfunction-associated steatohepatitis . The results, which were presented at the American Association for the Study of Liver Diseases  The Liver Meeting 2025, demonstrated clinically meaningful reductions in HbA1c, improvements in liver inflammation and fibrosis, and favorable changes in plasma lipidomic profiles after 16 weeks of treatment. The data suggest vanoglipel's potential to address both hepatic and metabolic factors in MASH. The findings were shared during a poster presentation on November 10, 2025, and the poster is available on the MetaVia website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5MWT6x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2581509622","title":"Metavia Inc. Unveils Pipeline Advances Targeting Obesity and MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2581509622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581509622?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:44","pubTimestamp":1762436691,"startTime":"0","endTime":"0","summary":"Metavia Inc. has presented new clinical data on its pipeline targeting cardiometabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis . The company highlighted its lead candidate DA-1726, a novel GLP1R/GCGR dual agonist, which demonstrated weight loss of up to 6.3% and reductions in fasted glucose and waist circumference over a 26-33 day period in a Phase 1 study. The candidate was generally well-tolerated, with mild gastrointestinal events reported and no treatment-related discontinuations. Metavia also reported positive Phase 2a top-line data for Vanoglipel  in MASH, confirming primary endpoint achievement and a favorable safety profile. Additional dose-finding and longer-duration studies are ongoing. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9qfHnV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2581096148","title":"MetaVia Q3 EPS $(0.14) Beats $(0.25) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096148","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096148?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:41","pubTimestamp":1762436484,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 43.78 percent. This is a 74.55 percent increase over losses of $(0.55) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48685184/metavia-q3-eps-0-14-beats-0-25-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","USJW.SI","SQQQ","TQQQ","NVIW.SI","QID","USAW.SI","MTVA","MNQmain","BK4139","NQmain","PSQ",".IXIC","QLD"],"gpt_icon":0},{"id":"2581909684","title":"Metavia Inc. reports third quarter 2025 results and updates on clinical programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581909684","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581909684?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:31","pubTimestamp":1762435912,"startTime":"0","endTime":"0","summary":"Metavia Inc. reported total other income of $0.6 million for the nine months ended September 30, 2025, down from $0.8 million for the same period in 2024, mainly due to $0.3 million in lower interest income, net, and partially offset by a $0.1 million increase in gain from the change in fair value of warrant liabilities. For the third quarter ended September 30, 2025, total other income was $0.1 million, compared to $0.6 million in the third quarter of 2024, reflecting a $0.2 million decrease in interest income and a $0.4 million change in the fair value of warrant liabilities. Cash stood at $14.3 million as of September 30, 2025, compared to $16.0 million as of December 31, 2024, with the company expecting this cash position to fund operations into 2026. During the period, Metavia dosed the first patient in the 8-week 48 mg MAD cohort of its Phase 1 clinical trial for DA-1726 in obesity, with top-line data expected by year-end 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7tJtJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2581619807","title":"MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2581619807","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581619807?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:03","pubTimestamp":1762290220,"startTime":"0","endTime":"0","summary":"MetaVia Inc. announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors, at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, GA. The Phase 1 study demonstrated favorable safety and tolerability, as well as a pharmacokinetic profile supporting once-weekly dosing. Meaningful reductions in body weight and waist circumference were observed after four weeks of treatment. Additionally, in pre-clinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide and showed superior lipid-lowering effects. Results from an extended Phase 1 cohort evaluating a higher 48 mg dose are expected later in 2025. The data have not yet been presented and are scheduled for release at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLb7lGj7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2580343211","title":"MetaVia Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580343211","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580343211?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:22","pubTimestamp":1762179728,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of22cents a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF1AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2578622384","title":"Metavia Inc. Advances Obesity Treatment with New Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2578622384","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578622384?lang=en_us&edition=fundamental","pubTime":"2025-10-28 02:12","pubTimestamp":1761588732,"startTime":"0","endTime":"0","summary":"Metavia Inc. (($MTVA)) announced an update on their ongoing clinical study. Study Overview: Metavia Inc. (MTVA) has initiated a Phase 1 clinical st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metavia-inc-advances-obesity-treatment-with-new-clinical-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metavia-inc-advances-obesity-treatment-with-new-clinical-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2576517338","title":"MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576517338","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576517338?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:31","pubTimestamp":1760963488,"startTime":"0","endTime":"0","summary":"MetaVia Inc., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor  and glucagon receptor . The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL8PNqyk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":1},{"id":"2575300218","title":"Metavia Inc. to Present at H.C. Wainwright Liver Disease Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575300218","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575300218?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:31","pubTimestamp":1760445084,"startTime":"0","endTime":"0","summary":"Metavia Inc., a clinical-stage biotechnology company focused on cardiometabolic diseases, will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on October 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL4gNq5v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2564373499","title":"Metavia Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2564373499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564373499?lang=en_us&edition=fundamental","pubTime":"2025-09-04 18:19","pubTimestamp":1756981173,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nFWN3UR0DK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2558647436","title":"MetaVia Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2558647436","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558647436?lang=en_us&edition=fundamental","pubTime":"2025-08-12 21:30","pubTimestamp":1755005451,"startTime":"0","endTime":"0","summary":"MetaVia Inc reports results for the quarter ended June 30 - Earnings SummaryMetaVia Inc MTVA.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended June 30, higher than the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U4122:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2558441579","title":"MetaVia Inc  expected to post a loss of 32 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558441579","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558441579?lang=en_us&edition=fundamental","pubTime":"2025-08-09 02:00","pubTimestamp":1754676027,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of32cents a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U037U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2557591304","title":"Metavia Inc. Unveils New Presentation Highlighting Advances in Cardiometabolic Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2557591304","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557591304?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:44","pubTimestamp":1754599486,"startTime":"0","endTime":"0","summary":"Metavia Inc., a clinical-stage biotech company focused on cardiometabolic diseases, recently presented updates on their pipeline targeting obesity and MASH with next-generation therapeutics. Key highlights include the development of DA-1726, a novel GLP1R/GCGR dual agonist for obesity, which has shown no treatment-related discontinuations and mild gastrointestinal events in Phase 1 trials. The company also shared promising results from DA-1241 for MASH, which met its primary endpoint and demonstrated direct hepatic effects in Phase 2a trials. Metavia plans to pursue further studies and regulatory milestones in the coming years. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL97snkm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2557156643","title":"Metavia Reports Second Quarter 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557156643","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557156643?lang=en_us&edition=fundamental","pubTime":"2025-08-07 21:10","pubTimestamp":1754572256,"startTime":"0","endTime":"0","summary":"Aug 7 (Reuters) - MetaVia Inc ::*METAVIA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE*METAVIA INC - QTRLY LOSS PER SHARE $0.26  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 07-AUG-202512:31:04.32 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nRSDXVr1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2557634705","title":"MetaVia Q2 EPS $(0.26) Beats $(0.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557634705","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557634705?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:34","pubTimestamp":1754570082,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 85.95 percent increase over losses of $(1.85) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46960259/metavia-q2-eps-0-26-beats-0-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2557655015","title":"Metavia Inc. Reports Q2 2025 Results: Net Loss Narrows to $4M, EPS Improves to $0.26 from $1.85 Year-Over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2557655015","media":"Reuters","labels":["dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557655015?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:31","pubTimestamp":1754569894,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on August 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL9MCKTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2557563463","title":"Metavia Inc - Qtrly Shr Loss $0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2557563463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557563463?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:31","pubTimestamp":1754569864,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nTUABKQVPF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2557641377","title":"BRIEF-Metavia Extends 48 Mg MAD Portion Of Its Phase 1 Clinical Trial Of Da-1726 For Treatment Of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2557641377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557641377?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:51","pubTimestamp":1754484684,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Extends 48 Mg MAD Portion Of Its Phase 1 Clinical Trial Of Da-1726 For Treatment Of Obesity Aug 6 (Reuters) - MetaVia Inc MTVA.O:METAVIA EXTENDS 48 MG MAD PORTION OF ITS PHASE 1 CLINICAL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUAFPQQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2557437294","title":"MetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2557437294","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557437294?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:31","pubTimestamp":1754483483,"startTime":"0","endTime":"0","summary":"MetaVia Inc. , a biotechnology company focused on cardiometabolic diseases, has announced an extension of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist targeting obesity. The trial's 48 mg multiple ascending dose cohort has been extended to 8 weeks, with a fifth weekly dose administered to the first patient. This extension aims to assess early efficacy, safety, and patient tolerability with longer-term exposure, and explore the non-titrated maximum tolerated dose. Previously reported data from the 32 mg dose showed promising results in weight loss and waist reduction with favorable safety profiles. Top-line data from the extended trial is anticipated in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL58HMgK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2557742713","title":"Metavia Extends 48 Mg Mad Portion of Its Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2557742713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557742713?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:31","pubTimestamp":1754483462,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUAFPQQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}